Transcode Therapeutics Inc

RNAZ

9.701USD

+0.201+2.11%

Market hours （ET）Quotes delayed by 15 min

Transcode Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

312 / 501

Overall Ranking

642 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

--

Current Rating

10.000

Target Price

+2266.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Transcode Therapeutics Inc Highlights

StrengthsRisks

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.

Fairly Valued

The company’s latest PE is -0.21, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 41.44K shares, decreasing 52.90% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 6.54K shares of this stock.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

The company’s current valuation score is 6.38, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.21, which is -261.33% below the recent high of 0.33 and -13980.49% above the recent low of -29.02.

Score

Industry at a Glance

Previous score

6.38

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 312/501

No Data

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.04. The average price target for Transcode Therapeutics Inc is 10.00, with a high of 10.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 1.01, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 19.38 and the support level at 8.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.00

Change

0.01

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Goldman Sachs & Company, Inc.

28.04K

--

The Vanguard Group, Inc.

Star Investors

6.54K

--

Geode Capital Management, L.L.C.

4.50K

+34.37%

UBS Financial Services, Inc.

1.43K

-84.81%

Tracy (Thomas Joseph)

1.25K

--

Private Capital Management, LLC

482.00

-25.04%

Tower Research Capital LLC

402.00

+630.91%

SBI Securities Co., Ltd.

10.00

-23.08%

RBC Dominion Securities, Inc.

9.00

--



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 1.50. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.

Transcode Therapeutics Inc

RNAZ

1.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Amicus Therapeutics Inc

FOLD

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.36 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment